It is well known that drug resistance to treatment is the central barrier to the success of AML therapy, and the main influencing factor is the excessive expression of drug-resistant proteins such as P-gp encoded by MDR1 in cancer cells, which induces chemotherapy failure in patients. Here, PGP is linked to acute myeloid leukemia.